Novel biomarkers and strategies for HCC diagnosis and care.

Authors :: Wang AE
Leven EA
Grinspan LT
Villanueva A
Source :: Clinical liver disease [Clin Liver Dis (Hoboken)] 2024 May 03; Vol. 23 (1), pp. e0152. Date of Electronic Publication: 2024 May 03 (Print Publication: 2024).
Publication Year :: 2024
Abstract: Competing Interests: Augusto Villanueva has received consulting fees from FirstWorld, Pioneering Medicine and Genentech; advisory board fees from BMS, Roche, Astra Zeneca, Eisai, and NGM Pharmaceuticals; and research support from Eisai. He has stock options from Espervita and Atzeyo. He is listed as an inventor on a patent related to early detection of HCC (PCT/US20/61441), and funded by the NIH (1U01CA283931-01). The remaining authors have no conflicts to report.<br /> (Copyright © 2024 American Association for the Study of Liver Diseases.)